761 related articles for article (PubMed ID: 31537750)
1. Novel Therapeutic Approaches Targeting the Renin-Angiotensin System and Associated Peptides in Hypertension and Heart Failure.
Arendse LB; Danser AHJ; Poglitsch M; Touyz RM; Burnett JC; Llorens-Cortes C; Ehlers MR; Sturrock ED
Pharmacol Rev; 2019 Oct; 71(4):539-570. PubMed ID: 31537750
[TBL] [Abstract][Full Text] [Related]
2. Recent changes in the landscape of combination RAS blockade.
Epstein BJ; Smith SM; Choksi R
Expert Rev Cardiovasc Ther; 2009 Nov; 7(11):1373-84. PubMed ID: 19900020
[TBL] [Abstract][Full Text] [Related]
3. Effects of renin-angiotensin system inhibition on end-organ protection: can we do better?
Weir MR
Clin Ther; 2007 Sep; 29(9):1803-24. PubMed ID: 18035185
[TBL] [Abstract][Full Text] [Related]
4. Novel Cardiac Intracrine Mechanisms Based on Ang-(1-12)/Chymase Axis Require a Revision of Therapeutic Approaches in Human Heart Disease.
Reyes S; Varagic J; Ahmad S; VonCannon J; Kon ND; Wang H; Groban L; Cheng CP; Dell'Italia LJ; Ferrario CM
Curr Hypertens Rep; 2017 Feb; 19(2):16. PubMed ID: 28233239
[TBL] [Abstract][Full Text] [Related]
5. Novel therapies blocking the renin-angiotensin-aldosterone system in the management of hypertension and related disorders.
Krum H; Gilbert RE
J Hypertens; 2007 Jan; 25(1):25-35. PubMed ID: 17143168
[TBL] [Abstract][Full Text] [Related]
6. Renin inhibition--benefit beyond hypertension control.
Kher V
J Assoc Physicians India; 2009 Jul; 57():518-20, 525. PubMed ID: 20329413
[TBL] [Abstract][Full Text] [Related]
7. AHU377+Valsartan (LCZ696) Modulates Renin-Angiotensin System (RAS) in the Cardiac of Female Spontaneously Hypertensive Rats Compared With Valsartan.
Zhao Y; Ma R; Yu X; Li N; Zhao X; Yu J
J Cardiovasc Pharmacol Ther; 2019 Sep; 24(5):450-459. PubMed ID: 31023080
[TBL] [Abstract][Full Text] [Related]
8. Development of inhibitors of the aspartyl protease renin for the treatment of hypertension.
Scott BB; McGeehan GM; Harrison RK
Curr Protein Pept Sci; 2006 Jun; 7(3):241-54. PubMed ID: 16787263
[TBL] [Abstract][Full Text] [Related]
9. Pharmacotherapy: Optimal blockade of the renin-angiotensin-aldosterone system.
Nussberger J; Bohlender J
Nat Rev Cardiol; 2013 Apr; 10(4):183-4. PubMed ID: 23478259
[TBL] [Abstract][Full Text] [Related]
10. Have the renin-angiotensin-aldosterone system perturbations in cardiovascular disease been exhausted?
Mansur SJ; Hage FG; Oparil S
Curr Cardiol Rep; 2010 Nov; 12(6):450-63. PubMed ID: 20827517
[TBL] [Abstract][Full Text] [Related]
11. Renin inhibition: a new modality for hypertension management.
Siragy HM
Curr Hypertens Rep; 2007 Aug; 9(4):291-4. PubMed ID: 17686379
[TBL] [Abstract][Full Text] [Related]
12. [The future of renin inhibition].
Uresin AY; Baran E
Turk Kardiyol Dern Ars; 2009 Oct; 37 Suppl 7():32-8. PubMed ID: 20019475
[TBL] [Abstract][Full Text] [Related]
13. Blocking the renin-angiotensin system: dual- versus mono-therapy.
Ravandi A; Teo KK
Expert Rev Cardiovasc Ther; 2009 Jun; 7(6):667-74. PubMed ID: 19505282
[TBL] [Abstract][Full Text] [Related]
14. Is aliskiren superior to inhibitors of angiotensin-converting enzyme and angiotensin receptor blockers in renin-angiotensin system blockade?
Gerc V; Buksa M; Loza V; Kulic M
Med Arh; 2009; 63(6):343-9. PubMed ID: 20380117
[TBL] [Abstract][Full Text] [Related]
15. RAS blockade with ARB and ACE inhibitors: current perspective on rationale and patient selection.
Werner C; Baumhäkel M; Teo KK; Schmieder R; Mann J; Unger T; Yusuf S; Böhm M
Clin Res Cardiol; 2008 Jul; 97(7):418-31. PubMed ID: 18454336
[TBL] [Abstract][Full Text] [Related]
16. Dual renin-angiotensin system inhibition for prevention of renal and cardiovascular events: do the latest trials challenge existing evidence?
Mallat SG
Cardiovasc Diabetol; 2013 Jul; 12():108. PubMed ID: 23866091
[TBL] [Abstract][Full Text] [Related]
17. Renin-angiotensin system blocking drugs.
Robles NR; Cerezo I; Hernandez-Gallego R
J Cardiovasc Pharmacol Ther; 2014 Jan; 19(1):14-33. PubMed ID: 24038019
[TBL] [Abstract][Full Text] [Related]
18. Comparison of type 1 angiotensin II receptor blockers and angiotensin converting enzyme inhibitors in the treatment of hypertension.
Weber MA
J Hypertens Suppl; 1997 Dec; 15(6):S31-6. PubMed ID: 9493125
[TBL] [Abstract][Full Text] [Related]
19. The sudden demise of dual renin-angiotensin system blockade or the soft science of the surrogate end point.
Messerli FH
J Am Coll Cardiol; 2009 Feb; 53(6):468-70. PubMed ID: 19195602
[TBL] [Abstract][Full Text] [Related]
20. Renin-angiotensin system blockade at the level of the angiotensin converting enzyme or the angiotensin type-1 receptor: similarities and differences.
Stergiou GS; Skeva II
Curr Top Med Chem; 2004; 4(4):473-81. PubMed ID: 14965313
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
